Endogenous testosterone does not improve prediction of incident cardiovascular disease in a community-based cohort of adult men: results from the Tehran Lipid and Glucose Study

Hatami, Hossein; Parizadeh, Donna; Tohidi, Maryam; Tehrani, Fahimeh Ramezani

doi:10.1080/13685538.2018.1466876

Cited by 5 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…30 Among these, FRS and PCE are frequently used. 6,30,31 Nevertheless, nowadays, efforts have been made to introduce more comprehensive CVD risk predictive assessment tools by adding biochemical and imaging parameters, to previous traditional ones, such as coronary artery calcification, 4,9,32 carotid intima-media thickness, 33 ankle-brachial index, brachial flow-mediated dilation, high-sensitivity C-reactive protein, family history of CHD, 4 microalbuminuria, chronic kidney disease, 34 and hemoglobin A1C. 11 For instance, data from the Rotterdam study on 2,153 asymptomatic participants showed that, for the outcome CHD, the C statistic improved from 0.693 for the FRS refitted model to 0.743, 0.740, and 0.749 by the addition of coronary, aortic arch, and carotid calcium, respectively.…”

Section: Discussionmentioning

confidence: 99%

Does the addition of serum antimüllerian hormone concentrations to the Framingham Risk Score and Pooled Cohort Equations improve the prediction of cardiovascular disease?

et al. 2023

Self Cite

View full text Add to dashboard Cite

Objective: The current study aimed to examine the added value of serum antimüllerian hormone (AMH) concentration to the Framingham Risk Score (FRS) and Pooled Cohort Equations (PCE) in predicting the risk of cardiovascular disease (CVD) in women of reproductive age.Methods: Women 30 years and older were considered eligible for this population-based prospective study. The univariate and multivariate Cox proportional hazard models were used to evaluate the association between the serum concentrations of AMH and the risk of CVD.Results: In the enhanced model, which integrated AMH into FRS and PCE and was adjusted for family history of premature CVD, AMH showed a significant association with the risk of CVD during a 19-year follow-up of 800 women (hazard ratio, 0.77 [95% CI, 0.60-0.99] and hazard ratio, 0.64 [95% CI, 0.48-0.84], respectively). According to the likelihood-ratio test, the addition of AMH measurements to FRS and PCE could significantly improve the risk prediction of CVD ( P = 0.02 and P < 0.001, respectively); however, the integration of this biomarker did not improve the classification of risk categories.Conclusions: The present findings revealed that the addition of serum AMH concentrations to FRS and PCE could potentially improve the risk prediction of CVD.

show abstract